An assembled molecular signaling map of interleukin-24: a resource to decipher its multifunctional immunoregulatory role in pathophysiological conditions.

Interleukin 24 (IL-24) is a multifunctional cytokine belonging to the IL-10 subfamily with immunomodulatory functions ( 1 – 3 ). It is also known as melanoma differentiation-associated gene-7 (MDA-7), as it was first isolated from growth-arrested and terminally differentiated human melanoma cells using subtractive hybridization ( 4 ). It is also known as ST16 (suppressor of tumorigenicity-16) and was renamed IL-24 after the discovery of cell surface receptors of MDA-7 ( 5 – 9 ). IL-24, with its unique cytokine properties, has dual functions as a pro- and anti-inflammatory agent and as a tumor suppressor cytokine ( 10 , 11 ). It exhibits the ability to selectively induce cell death in various cancer cells ( 2 , 10 , 11 ). It is a pleiotropic cytokine studied in several inflammatory and cancer conditions, known for its characteristics to modulate immune cell activity with diverse functions depending on the target cell type and disease state ( 10 ). This secretory cytokine consists of 206 amino acid residues, with 51 amino acids serving as a signal peptide ( 12 ). The human IL-24 gene is located on chromosome 1, within a 195-kb cytokine cluster named the “IL-10 family gene cluster,” comprising four genes, IL-10, IL-19, IL-20, and IL-24. IL-24 shares a high sequence homology at the amino acid level across the species ( 9 ). IL-24 is produced by immune cells of both lymphoid and myeloid lineages when activated with certain lipopolysaccharides or specific cytokines and non-immune cells, including melanocytes ( 1 , 12 ). It originates mainly from activated monocytes and T helper 2 cells. IL-24 functions as a classical cytokine, exerting its effects through its cell-surface heterodimeric receptor complex (IL-20R1 and IL-20R2; IL-22R1 and IL-20R2). IL-20R1 and IL-22R1 pair with the IL-20R2 chain to form a heterodimeric receptor complex, thereby inducing cell signaling events ( 13 , 14 ). The IL20R1 and IL22R1 expression levels determine the quantity of these two receptor complexes. The expression of the three subunits was consistent in the majority of the tissues and cellular conditions ( 6 , 15 ). This heterodimeric receptor complex is a part of the IL-10 receptor family and is shared among cytokines within this family, which displays a 20-30% sequence homology ( 6 – 8 ). The utilization of shared receptors is a common mechanism within the cytokine family, leading to the cross-talk and precise regulation of cellular response in the immune system ( 9 ). Moreover, IL-24 may interact differently with type I and type II receptor heterodimers, exerting non-redundant and unique biological activities ( 15 ). In addition to receptor-ligand interaction-induced signaling events, IL-24 initiates multiple signaling events intracellularly, independent of its non-cognate receptors ( 16 , 17 ). IL-24 is a versatile cytokine that can regulate anti-tumor activity, immune response, tissue homeostasis, and host defense mechanisms ( 3 , 10 ). This multifunctional protein affects broad types of cancer and has a crucial role in regulating cell proliferation, survival, tumor suppression, differentiation, and apoptosis-inducing properties ( 18 , 19 ). It is well-known for its multi-pronged indirect anti-tumor activities, including the induction of the release of other cytokines, resulting in immunomodulatory activities ( 1 , 20 , 21 ). It can also regulate the proliferation and activation of CD4+ and CD8+ T cell populations ( 22 , 23 ). Due to its remarkable tumor-suppressing ability, IL-24 shows greater potential for advanced targeted cancer therapy. Recent reports have demonstrated the immunotherapeutic potential of IL-24, with its immunomodulatory activity combined with the apoptotic and anti-angiogenic properties, strengthening its utility in cancer immunotherapy ( 24 – 28 ). A Phase I clinical trial using an adenovirus vector expressing IL-24 (Ad-IL-24) has documented the T cell activation and cytokine release for the eradication of tumor cells ( 28 – 36 ). The strategic utilization of IL-24 in cancer therapy leads to a promising method of precision medicine, navigating toward an effective approach in cancer treatment. Despite the importance of IL-24-mediated signaling, comprehensive information on IL-24-mediated signaling events is currently limited. The KEGG and Reactome pathway databases only offer a general overview of the signaling modules regulated by IL-24. The potential roles of IL-24 as a cytokine in the form of a comprehensive signaling pathway map will encourage further investigation into IL-24-mediated cellular events. This may lead to unraveling specific roles of individual molecules and modules in various pathophysiological conditions, including cancer, inflammatory disorders, and other diseases. Previously, we compiled the signaling events of several other cytokines, including CCL18, CCL19, IL-11, IL-17, IL-19, and 1L-20, through the documentation of their cell-specific functional roles attributed to diverse experimental conditions ( 37 – 41 ). Similarly, the study-centric molecular reactions of IL-24 were assembled, adding them to the compendium of cytokine signaling pathway maps for gene set enrichment analyses.

To create a comprehensive IL-24 signaling pathway map, a literature survey was carried out on IL-24 signaling. The search terms used were “IL-24 AND Signaling,” and the articles were retrieved from PubMed. The abstract of research articles describing the signaling events induced by IL-24 was manually screened to select the relevant ones. The experimental datasets were limited to the signal transduction events induced by IL-24, excluding the knock-out and co-expression studies. The curated datasets encompass studies pertaining to diseases such as cancer, infectious, and inflammatory conditions. The data related to signaling events induced by IL-24 were then manually annotated and cataloged according to the PathBuilder criteria ( Figure 1 ) ( 42 ). IL-24-induced molecular events such as protein-protein interactions, protein expression, gene regulation events, activation/inhibition events, enzyme catalysis/post-translational modifications (PTM), molecular association, and protein translocation were curated from the research articles ( 43 ). The protein and gene expression events were cataloged for overexpressed (fold change >1.3, p-value <0.05) and downregulated (fold change <0.76, p-value <0.05) molecules, as devised in each of the studies. All possible PTM events, including acetylation, ubiquitination, denitrosylation, N-glycosylation, phosphorylation, and dephosphorylation, with their site-specific information, were annotated within the pathway map and are delineated with different colors. Further, the translocation events were categorized based on the transportation of proteins within the cellular organelles comprising the nucleus, plasma membrane, cytoplasm, mitochondria, and Golgi complex. The proteins and genes were mapped to their corresponding Entrez Gene ID to annotate the data in a standardized format. Besides the proteins, the involvement of small molecules or second messengers such as reactive oxygen species (ROS), Ca 2+ , and cAMP was also noted. Individual study-centric signaling events and their related disease conditions and cell type-specific reaction events were documented. The data also included the type of experiments performed to detect and validate the expression of downstream molecules of IL-24 ligand-receptor interaction and the cell line/tissue used. The data on the synergistic activities of IL-24 were curated using the same data annotation strategy and included information on the impact of drugs and other molecules of therapeutic potential. A detailed workflow outlining the methodology for the IL-24 signaling pathway data curation, annotation, and map development. The workflow depicts the sequential steps used to develop the IL-24 signaling pathway map. The literature related to IL-24 signaling in cancer, infectious, and inflammatory disease conditions was manually screened, followed by the curation and annotation of the signaling events according to the NetPath criteria. Further, with the annotated data, a detailed signaling pathway map was developed. The annotated molecules, reactions, and disease-specific biological processes were manually drawn based on the topology as a signaling pathway map of IL-24 using the PathVisio (version 3) tool ( 44 ). The topology that represents the spatial order of the molecules was devised based on the directionality initiated by the IL-24 and its receptor interaction, as determined by studies using inhibitors or the established cascade of reactions. The protein-protein interaction network analysis was performed with IL-24, its receptors, and downstream targets. The analysis was carried out using the tool STRING database with a confidence score of >0.7 ( 45 ). To enrich the functional clusters, the network was imported into the Cytoscape tool v 3.10.2, and the algorithm Molecular Complex Detection (MCODE) was applied ( 46 , 47 ). MCODE identifies the clusters based on their local neighborhood density and expands from highly connected hubs. Additionally, publicly available omics datasets were analyzed to provide supporting evidence for the pathway map. The PBMC transcriptomic data were retrieved from the NCBI GEO DataSets and analyzed using GEO2r to assess the expression of IL-24 across various disease conditions. Similarly, differentially expressed proteins were obtained from the publicly available proteomic dataset, and the pathway enrichment analysis was performed using the Reactome database ( 48 ).

To develop the IL-24 signaling pathway map, a total of 697 articles were screened in PubMed using the search criteria described in the methods section. A total of 341 molecules involved in IL-24-mediated 602 signal transduction events were manually vetted from the 191 studies. These events include 79 enzyme-substrate reactions, 15 protein-protein interactions, 76 activation/inhibition reactions, 10 protein translocation events, 262 protein expressions, and 171 gene regulation events identified from the annotations of these selected articles. Information on differentially regulated mRNA/proteins responding to IL-24 stimulation is also available. Among the 171 genes, 93 were overexpressed, and 78 were downregulated, whereas in 262 proteins, 132 were overexpressed, and 130 were downregulated. As far as we know, this is the first pathway resource that catalogs IL-24-mediated molecular reactions. The network map depicts the molecular events involved in a wide range of IL-24-induced processes, including host defense, tissue homeostasis, and immunological regulation in various physiological conditions. The study-centric molecular reactions of IL-24 in various pathological conditions comprising cancer, infection, and other diseases were manually annotated, assembled, and represented as a comprehensive signaling pathway map ( Figure 2 ). The detailed annotated data that were analyzed for building the IL-24 pathway map are provided in the Supplementary File S1 . As supported by the assembled data, the functional role of IL-24 is facilitated either through the heterodimeric receptor complexes (IL-20R1 and IL-20R2; IL-22R1 and IL-20R2) or intracellularly, independent of the receptors. The receptor-mediated functional role of IL-24 was observed to be initiated through both of these receptor complexes in the majority of the investigated studies. The IL-24-IL-20R1/IL-20R2 and IL-24-IL-22R1/IL-20R2 ligand-receptor interactions are reported to mediate the cellular responses through multiple signaling modules encompassing JAK-STAT, PI3K-AKT, mTOR, CHOP, MAPK, PERK, and PKR. This heterodimeric receptor complex is also shared within the other IL-10 cytokine family members, allowing an overlapping core signaling mechanism, particularly involving the IL-22R1 and IL-20R2 and the JAK-STAT signaling pathway in epithelial cells, keratinocytes, and immune cells ( 49 ). Even though IL-24 is structurally related to other IL-10 family members and shares some signaling machinery, it is unique in its anti-tumor properties, endoplasmic reticulum (ER) stress, and reactive oxygen species (ROS) production that induce selective toxicity in cancer cells ( 11 , 50 ). These intricate signaling networks contribute to the diverse physiological effects elicited by IL-24 in various biological contexts. The schematic representation of IL-24-induced signaling reactions. The signaling pathway map shows molecules associated with ligand-receptor interactions and IL-24 downstream molecular events. The pathway comprises the signaling modules such as activation/inhibition, enzyme catalysis, protein/gene regulatory events, molecular association, and translocation events induced by IL-24 toward its anti-tumor and immunoregulatory properties. These signaling events are represented with a specific type of edge and are color-coded as mentioned in the pathway legend. The pathway also includes information about the site and residues of post-translational modifications. The functions/processes linked to each signaling event, as annotated from the curated study, are displayed at the bottom of the pathway. The distinctive functions of IL-24 in cancer include tumor-specific killing through an integrated effect of apoptosis, leading to a potent “bystander” anti-cancer activity, inhibition of cell proliferation, migration, and angiogenesis ( 18 ). This cytotoxic activity could cause either growth arrest or apoptosis through various cellular mechanisms solely in cancer cells at the supraphysiological levels of IL-24. Meanwhile, IL-24, at its natural physiological level, is recognized to function regularly to maintain its cellular processes and immune responses. A potential explanation for this selectively induced apoptosis is the intrinsic biochemical distinctions between normal and cancer cells. This encompasses factors such as high ROS production, altered metabolism, reprogrammed signaling pathways, and oxidative and endoplasmic reticulum (ER) stress ( 51 ). The bystander activity of IL-24 induces anti-cancer effects on IL-24 target cells and influences the neighboring untreated cells. This intriguing property makes IL-24 a promising candidate for cancer therapy as it amplifies its therapeutic potential beyond the directly treated cells. The IL-24 expression in tumor cells is primarily derived from tumor-infiltrating immune cells, such as T cells and NK cells, rather than from the tumor cells themselves. Moreover, the cells transduced with IL-24 can secrete other cytokines acting on the adjacent tumor cells, exerting their apoptotic and anti-proliferative effects ( 11 ). The tumor suppressive activity of IL-24 has been widely studied in a broad range of cancers, including oral, breast, lung, cervical, and colorectal carcinoma ( 22 , 52 – 55 ). IL-24 modulates diverse apoptosis-related signaling pathways through the regulation of multiple apoptosis-effector proteins in various cancers. It promotes apoptosis through the extrinsic pathway, mediated by death receptors ( 56 , 57 ). It also invokes the intrinsic pathway, driven by the expression of Ataxia Telangiectasia Mutated protein ( ATM ) and TP53. This intricate network stimulates pro-apoptotic and inhibits anti-apoptotic molecules, culminating in the activation of caspases, orchestrating the subsequent cell death across diverse cancer types ( 58 – 60 ). Additionally, it initiates apoptosis through oxidative and ER stress by triggering the release of ROS, activation of PKR ( EIF2AK2 ) and multiple MAPKs, followed by the activation of ER stress markers, DNA damage-inducing proteins, and BiP ( HSPA4 ) ( 51 , 56 , 61 – 63 ). Despite the activation of apoptosis, IL-24 is also known to induce autophagy-associated cell death by the regulation of miR-221 and Beclin 1 ( BECN1 ) axis and direct activation of autophagy-related gene 5 ( ATG5 ) ( 64 , 65 ). Besides, IL-24 is well-known for the phosphorylation, activation, and nuclear translocation of the tumor suppressor protein TP53, resulting in cell proliferation arrest ( 66 ). Altogether, these combined actions culminate in the initiation of apoptosis within several cancer types. IL-24 exhibits potent anti-tumor activity, including anti-angiogenesis by suppressing endothelial cell markers such as vascular endothelial growth factors and CD34 . It induces cell cycle arrest (G2-M phase) by modulating cell cycle proteins such as CDKs, cyclins, and cell division cycle proteins. Further, it inhibits cancer cell adhesion and invasion by downregulating matrix metalloproteinases (MMPs) and adhesion molecules ( 67 – 70 ). IL-24 has also proven to be an anti-proliferative molecule, substantiated by its ability to reduce the expression of proliferation markers, Marker of Proliferation Ki-67 ( MKI67) , and Proliferating Cell Nuclear Antigen (PCNA ) ( 71 , 72 ). In addition, IL-24 has a significant role in impeding cancer stem cell maintenance and epithelial-to-mesenchymal transition (EMT), reversing drug resistance, and inducing cellular senescence in cancer cells. Additionally, it involves the inhibition of both Notch and the Wnt/β-catenin signaling pathways with the subsequent proteasomal degradation of β-catenin ( CTNNB1 ), and the ubiquitination and degradation of BCL2 ( 52 , 71 , 73 – 78 ). Beyond the intrinsic property of IL-24 as a cytotoxic and tumor-suppressant agent, numerous studies have investigated the utility of IL-24 with other drugs as a combinatorial drug administration approach in various diseases ( Figure 3 ). Research findings have demonstrated that combining multiple chemotherapeutic agents and radiation with IL-24 in cancer treatment has amplified the effectiveness of chemotherapy and radiotherapy in numerous cancers ( 79 – 81 ). Also, studies have shown that IL-24 promotes apoptosis in various cancer types, boosting its anticancer activity when used in conjunction with some anti-inflammatory drugs, pleiotropic cytokines, including IL-20, IFNG, IL-6, vitamin E, gamma-secretase, and other small-molecule inhibitors ( 82 – 84 ). Diagrammatic illustration of the synergistic activity of IL-24 along with the various drugs and therapeutic agents. The diagram summarizes the synergistic action of IL-24 and other pharmacological agents in various disease conditions. Key drugs and the cancer conditions indicated in the study are represented along with the amplified therapeutic responses. IL-24 can be a potent therapeutic agent against viral and bacterial infections like influenza, Human immunodeficiency virus (HIV), Mycobacterium , and Salmonella ( 85 ). As well, in inflammatory conditions such as endometriosis, inflammatory bowel diseases (IBD), asthma, and psoriasis, IL-24 has been observed to modulate inflammation-associated events ( 86 – 90 ). Higher expression levels of IL-24 have always been associated with chronic inflammation and autoimmune disorders such as psoriasis, arthritis, vascular permeability, and IBD ( 91 ). In chronic inflammatory conditions such as asthma, IL-24 contributes to inflammation by promoting EMT of alveolar cells and neutrophils ( 89 , 90 ). While in pathogenic infections, IL-24 induces an immune response through the secretion of cytokines such as IL-12, IL-23, IL-27, and IFNG ( 20 , 92 ). IL-24 induces cytokine secretion by the activation of SOCS proteins through the JAK-STAT pathway. The SOCS proteins are known to play an important role in IL-24 signaling cascades for various inflammatory and infectious conditions ( 14 ). The role of IL-24 in inflammatory diseases is context-specific, where it has been implicated in promoting inflammation in certain pathophysiological conditions. Similar to the case of cancer, IL-24 functions to reduce the proliferation and invasiveness of endometrial squamous cells (ESCs) in endometriosis, marked by the downregulation of MKI67 and PCNA . In addition, IL-24 also suppresses the macrophage-induced high viability and invasiveness of ESCs ( 88 ). Whereas, in IBD, recent studies have found that peripheral blood mononuclear cells (PBMCs) and epithelial cells secrete higher amounts of IL-24, resulting in the activation of extracellular matrix (ECM) and mucin proteins (collagens, fibronectins) contributing to the remodeling of the mucous layer in IBD ( 93 , 94 ). In other inflammatory conditions, such as psoriasis, IL-24 is highly stimulated and induces the expression of the inflammatory mediators, including Psoriasin, chemokine ligands ( 87 ). Furthermore, studies have proven that IL-24 can act as a protective agent and reverse the molecular events caused by the injuries induced by specific agents, such as H 2 O 2 and β-glycerophosphate ( 95 , 96 ). Similarly, in liver fibrosis, IL-24 functions to protect the liver from inflammation and injury. IL-24 protects the liver cells through the activation of anti-oxidant proteins and the reduction of ER stress-related DNA-damaging proteins, pro-apoptotic and pro-inflammatory proteins ( 97 , 98 ). Also, its potential as a therapeutic agent in central nervous system autoimmunity has been recently investigated, revealing that IL-24 suppresses ocular inflammation by markedly inhibiting the Th1 and Th17 cells differentiation and cytokine secretion from the ocular infiltrating pathogenic Th1 and Th17 cells ( 99 ). In inflammatory conditions, IL-24 plays a dual role in Th17 cells by promoting mitochondrial recruitment of STAT3, enhancing oxidative phosphorylation, and dampening the nuclear transcriptional activity of STAT3, thereby regulating the IL-10 expression and restraining the Th17-mediated immunopathology ( 100 ). Additionally, IL-24 also acts as a downstream regulator in the IL-17A-mediated signaling loop within Th17 cells, controlling the expression of other Th17-associated cytokines such as IL-17F and GM-CSF ( 101 ). Thereby, IL-24 effectively modulates the balance between inflammation and regulation in autoimmune diseases by orchestrating Th17 cell function and cytokine expression. Therefore, the intricate involvement of IL-24 in modulating immune responses and inflammatory processes unravels its potential as a therapeutic target in a range of inflammatory conditions. IL-24 is widely recognized as an immunomodulatory cytokine with the property to enhance the tumor-specific immune response and disrupt the tolerance toward tumor antigens ( 102 ). Recent reports indicate that IL-24 can augment CD4+ and CD8+ T cell populations and reduce T regulatory cells within tumor-infiltrating lymphocytes (TILs), suggesting IL-24-mediated anti-tumor immune responses in colorectal adenocarcinoma ( 22 ). Also, Ma et al. (2016) have reported IL-24 mediates tumor suppression through increased percentages of CD45+CD4+ and CD45+CD8+ cells and decreased percentage of CD45+CD4+Foxp3+ cells in IL-24-treated colon cancer ( 102 ). The enhanced cytolytic activity of CD8+ T cells was marked by the IFNG, granzymes, and perforins secretion stimulated by IL-24 ( 22 ). Moreover, IL-24 markedly enhanced the mRNA expression of the transcription factor T-bet (Th1 transcriptional factor) to activate CD4+ T cells. It also inhibits the expression of a T regulatory cell activation marker, transcriptional factor Forkhead Box P3 (FOXP3), ultimately reducing the T regulatory cells in colorectal carcinoma ( 22 , 102 ). Alongside, it also activates and enhances the functions of the cluster of differentiation 80 and 86 ( CD80, CD86 ) proteins that are known for the transduction of secondary signals for T-cell activation. Furthermore, it also stimulates innate and adaptive immune responses in myelogenous leukemia cells through the production of ligands ( MICA and MICB ) for Killer Cell Lectin Like Receptor K1 ( KLRK1 ) on NK and T cells ( 103 ). Besides its intrinsic immunoregulatory functions, IL-24 can induce the secretion of other cytokines and modulate its activity in diverse pathological conditions ( 104 , 105 ). IL-24 stimulates the secretion of IL-6, IL-12, IL-27, and IFNG in cancer and infectious disease conditions. Thereby, IL-24 plays a significant role in regulating the immune response against tumorigenesis by reversing the immunosuppressive tumor microenvironment and promoting anti-tumor immunity ( 103 ). Additionally, in infectious disease conditions, it stimulates the immune response through the recruitment of CD4+, CD8+ T cells, and neutrophils by the activation of T-Cell-Specific T-Box Transcription Factor ( TBX21 ), leading to the secretion of IFNG and several other interleukins ( 106 ). This orchestrated immune activation by IL-24 plays a crucial role in combating pathogens, external antigens, and tumor cells, thereby promoting the host-defense mechanisms. The demonstration and visualization of the mechanisms of IL-24-mediated immunoregulation facilitate and aid in developing and utilizing IL-24 therapeutic approaches. Recent reports have proven the efficacy of IL-24 in enhancing CAR-T cell therapy against cancer stem cells (CSCs) that exhibit therapeutic resistance ( 25 ). The study by Hu et al. (2021) has reported that IL-24 potentially enhances the vitality of T cells, which is a common cell resource for CAR-T products, and significantly inhibits the viability and proliferation of cancer cells in leukemia and lymphoma ( 26 ). In addition, it was found that IL24-potentiated T-cell expansion and increased tumor infiltration significantly inhibited the cancer progression. Therefore, arming T cells with IL-24 shows the capabilities of tumor eradication and T-cell expansion within the tumor microenvironment. This highlights a promising approach of cellular immunotherapy that inhibits tumor escape ( 27 ). Moreover, through the annotation of IL-24 signaling mechanisms, we identified that IL-24 has the potency to significantly suppress the expression and activity of the T regulatory cell transcription factor, FOXP3, in cancer cells and infectious disease conditions. This transcription factor is well known for activating T regulatory cells that impair the treatment response in cancer immunotherapy ( 107 ). Extensive research activities are carried out to suppress this transcription factor as a cancer therapeutic approach ( 108 ). However, the ability of IL-24 to specifically target and suppress the function of FOXP3 remains inadequately investigated. Therefore, with this signaling pathway map, we were able to showcase all possible signaling mechanisms, primarily in cancer as well as in other inflammatory and infectious diseases. IL-24 stands out as a potent therapeutic agent, with supporting evidence highlighting its potential in developing advanced and personalized cancer therapeutics. The current pathway model serves as a tool that integrates molecular-level information derived from individual studies and does not represent a temporally orchestrated network within a single cell; rather, it represents standalone findings from each study. This applies to all pathway models available to date and is further augmented by the limitations in their effective visualization ( 37 , 43 , 109 ). In a way, most maps are static, considering the signaling network highly spatiotemporal and dynamic. However, the pathway model represents the collective information on the molecules and their reactions that are identified to be perturbed upon IL-24 stimulation into a computationally encoded form for incorporation into enrichment tools. These details, which are otherwise scattered across the literature, would be time-consuming for individual researchers to compile into pathway models. Additionally, the present study does not provide new in vivo or clinical validation. However, all the signaling events incorporated into the pathway were curated from experimentally validated studies, reflecting the available literature up to the time of publication. Even though challenged by the above limitations, the current model serves as a reference platform and database to update molecular data as more studies on IL-24 become available. We also aim to refer to notable studies in the map to ensure transparency and to support future updates as more data becomes available. Furthermore, to demonstrate the utility of the annotated signaling pathway map serving as a framework for applying gene set enrichment analysis, we mapped it into the protein-protein interaction network comprising IL-24, its receptors, and downstream targets. The analysis highlighted the various hub genes, including key signaling modules such as JAK-STAT, SOCS, PI3K, PTK2, and MAPK, together with apoptosis and cell cycle regulator proteins ( Figure 4 ). This emphasizes the role of the curated signaling map in the detection of enriched signaling modules and the selection of candidate molecules for further analysis. Additionally, we looked into the publicly available transcriptomic profiles of peripheral blood mononuclear cells in cancer and infectious disease conditions. We identified three transcriptomic datasets where IL-24 expression was detected ( 110 – 112 ). Notably, IL-24 was consistently downregulated in cancer and inflammatory conditions, together with the suppression of anti-tumor cytokine genes within the immunosuppressive microenvironment. Whereas, in the infectious disease condition of tuberculosis, IL-24 was found to be overexpressed, indicating its anti-infectious property. This reinforces the immunomodulatory role of IL-24 and represents the utility of this curated pathway map to elucidate disease-gene association and its expression changes for further functional analysis. Protein-protein interaction network analysis. The figure represents the interaction network analysis of IL-24, its receptors, and downstream targets. The proteins are color-coded according to five distinct clusters based on the hub genes analysis. The hub genes are highlighted within each cluster, and the blue colored nodes depict the proteins that interact directly or indirectly with these hub genes. Further, to complement the signaling pathway, we performed a pathway enrichment analysis with the differentially expressed proteins identified from the publicly available proteomic dataset of IL-24-treated cervical cancer cells ( 113 ). The analysis revealed significantly enriched pathways, including apoptosis, immunomodulatory pathways, and cell cycle regulations ( Supplementary Figure S1 ). These enriched pathways align with the key signaling modules annotated in the pathway map of IL-24, further supporting the role of IL-24 in tumor suppression and immunoregulation. This integration demonstrates the utility of the application of this signaling pathway map in gene set enrichment analysis pipelines, offering a valuable resource for future studies in the analysis of high-throughput data.

A majority of studies have focused on the role of IL-24 in the pathophysiology of diseases, as this multi-functional cytokine serves as both a tumor suppressant and an agent with pro- and anti-inflammatory properties. IL-24 is very well known for its tumor-suppressive activity and is utilized as a therapeutic agent in cytokine therapy against a broad spectrum of cancers. The signaling pathway map of IL-24 provides a detailed illustration of its downstream molecular targets and their signaling mechanisms. Hence, this pathway map would accelerate clinical applications of IL-24 as a therapeutic target for various disorders, to its potential as a prominent therapeutic agent in cancer, and to reshape the tumor microenvironment. The signaling pathway map developed in this study provides a framework to visualize the molecules and their reactions reported to be induced by IL-24 in various disease conditions. This comprehensive signaling pathway can help identify gaps in signaling events and investigate further molecular reactions, including dynamic protein complexes associated with IL-24 signaling across various pathophysiological conditions. In the current scenario, the involvement of IL-24 and its signaling components in various clinical/experimental global omics datasets is not ensured through gene set enrichment analysis approaches. This is primarily due to the lack of availability of its pathway model in the existing enrichment tools. Further enrichment of datasets derived from high-throughput approaches such as single-cell transcriptomics and proteomics may provide deeper insights into the role of IL-24 in health and disease, leading to an expansion of the pathway. To enable its utility, the IL-24 map/model is made freely available in.gpml format for their conversion into other international standard exchange formats such as BioPAX, PSI-MI, and KEGGML for their incorporation into different enrichment analysis tools. To acquire its full potential, IL-24-mediated effects in diverse preclinical models should be validated for their efficacy across different biological conditions or engaged in studies toward patient stratification based on response to IL-24-targeted interventions. The combinatorial effects of IL-24 with other cytokines or their regulation under various disease conditions also demand further investigation. This model can be customized or enhanced by the users to engage them in the analysis of omics datasets by individual researchers. The IL-24 pathway model will be made available through the web portal ( https://ciods.in/il24/ ) to keep the pathway updated and provide it to the users.